Forward Pharma Receives Issue Notification for Erosion Matrix Patent in the U.S.
"This is further evidence of the progress we are making in our intellectual property estate. With patent protection extending into 2030 in the U.S., we believe that we have now established a long runway for our novel formulation of DMF, FP187," commented
The USPTO examiner allowed the erosion matrix patent application after considering opposition papers, including those of
Additional information on the patent, including the issue notification, is available by accessing the Patent Application Information Retrieval (PAIR) website http://pair.uspto.gov under patent application 13/143,498 entitled "Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix" (patent number 8,906,420).
Our principal executive offices are located at Østergade 24A, 1, 1100 Copenhagen K,
Forward Pharma A/S Media Contact:
Forward Looking Statements:
Certain statements in this press release may constitute "forward-looking statements" of the Company within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to: statements which contain language such as: "believe,""expect," "hope," "would" and "potential." Forward-looking statements are predictions only which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those expressed in such statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: the Company's ability to obtain, maintain and defend issued patents with protective claims; the commencement of any patent interference or infringement action; the Company's ability to prevail in or obtain a favorable decision in any such action; and the Company's ability to recover damages in any such action; uncertainties relating to our development plans; risks and uncertainties related to the scope, validity; and the enforceability of our intellectual property rights in general and the impact on us of patents and other intellectual property of third parties. Given the uncertainties, assumptions and risk factors associated with this type of information, including those described above, investors are cautioned that the information may not be appropriate for other purposes.